Starting out in science: Boston researchers share lessons from their first jobs

Thursday 26th July saw the launch of SciLogs.com, a new English language science blog network. SciLogs.com, the brand-new home for Nature Network bloggers, forms part of the SciLogs international collection of blogs which already exist in GermanSpanish and Dutch. To celebrate this addition to the NPG science blogging family, some of the NPG blogs are publishing posts focusing on “Beginnings”.

Participating in this cross-network blogging festival is nature.com’s Soapbox Science blogScitable’s Student Voices blog and bloggers from SciLogs.com, SciLogs.deScitable and Scientific American’s Blog Network. Join us as we explore the diverse interpretations of beginnings – from scientific examples such as stem cells to first time experiences such as publishing your first paper. You can also follow and contribute to the conversations on social media by using the #BeginScights hashtag.   

 

Click for video of Jerry De Zutter and others

A scientist’s first job can be a thrill, a terror, a challenge, a source of inspiration or the inspiration to do something different.  So say some of the researchers whose career paths led them through Kendall Square this week. Conversations inside and outside neighborhood labs and offices explored the question – What lessons did you learn when first starting out?

Some researcher had mentors — or at least people who gave them memorable advice. Jerry De Zutter met his first boss — Gary Barsomian of Genzyme – while playing Ultimate Frisbee.  De Zutter interned at Genzyme as an undergrad, worked at the Cambridge-based pharma for a year, and got some advice from Barsomian before heading to graduate school :“The one thing you want to make sure you do when your rise to the level of a PHD science, is to become an expert in something. “

De Zutter focused on the signal transduction processes that underlie neurodegeneration. After several jobs in the pharmaceutical industry, he now runs a team of researchers working on discovery and the pre-clinical pipeline at ALS Therapy Development Institute. The company is one of a growing number of non-profit pharmaceutical development projects.

On a break at a Kendall coffee shop, Deepti Sharma also said she had a supportive boss. Working with LC-MS ( liquid chromatography-mass spectrometry] at Advion, a company in Ithaca, New York, she said her supervisor encouraged her to take on more responsibility: “That gave me a good opportunity to explore the product development platform with full enthusiasm and energy,” she said. Sharma also got the best of both worlds – academic and industry. While at the company, she was able to work with Cornell professor Jack Henion, whom she described as “the father of LC-MS…It was as if I was working as  a student but in an innovative, fast-paced environment,” she said.

Not everyone queried in the square remembered an inspiring boss. Chris, a pharma chemist who asked that his last name not be used, said he had a supervisor with “a very serious temper problem” at his first job, which was in an academic lab. But, that isn’t what drove him out of the university setting and into the world of corporate science. Without a PhD, he didn’t see any future in academia.

Kathryn Erat

 When Kathryn Erat started her career in the 1950’s, she quickly stepped into the future.  A degree in math and physics landed her a job with a combustion engineering company working on power systems for nuclear submarines. After struggling for days to solve complex math problems, she suggested to her boss that they might be able to work more efficiently with a new form of technology – the computer. Back then, that meant a mainframe and a trip to New Jersey.

Two chemical engineers lunching outside a local biotech – Tanya and Hong – both faced the same problem when finding their first jobs in the US. The two women – who asked that their last names not be used – had to convince employers that the skills they learned in Communist countries would apply to work in this country. When Tanya, who was trained in the former Soviet Union, got her first job, she was grateful for the chance to prove herself: “For those who are not born in the States and do not have an American education, to find a first job is extremely challenging because you don’t have the right experience in this country. Your experience anywhere else seems to be absolutely irrelevant.”

Hong, who arrived from mainland China 20 years ago, said she had the same problem, but ended up landing a job with a helpful boss. Her first realization was that the U.S. drug development industry worked under a different set of rules.

“Twenty years ago in China, (regulations) were a lot looser,” she said. Here, for example “the regulations about patient safety are very strict.”

Computational biologist Kevin Galinksy spent two years at the J. Craig Venter Institute in Maryland before coming to the Broad Institute.  As a young scientist, he’s only worked in a wired world. So, the advice to publish or perish had a different meaning for him – he can post some of the code he’s developed on the web.

John Lincecum

Back at the ALS Therapy Development Institute, Director of Discovery John Lincecum, said he was interested in science and took premed course as an undergrad. But he decided to focus on the liberal arts and leave most of the science for grad school.

He fled the oil bust in his native Texas to look for work in then booming Massachusetts. Lincecum emphasized the science on his resume and was hired as a technician for a company now known as Charm Sciences, which was developing radioimmunoassays to test for penicillin levels in milk.

“I was absolutely terrified because my worry was that they would figure out I really wasn’t a scientist,” he said. “I was English major.”

His fears came true when he spent an entire week pressing the wrong button on a scintillation counter.  Instead of carefully measuring ionizing radiation, he was pushing the button for the timer.  He expected to get fired.  “But they were very patient,” he said. What he found was that the approach he had been counting on paid off:  “I felt all I had to do was — ask a lot of questions, be very, very enthusiastic and be willing to admit every mistake I made.”

 

 

 

New Kendall Square restaurant set up to host bio events like this one

When new drug development company H3 decided to throw a party to launch the opening of Kendall Square labs and offices, organizers didn’t have to go very far. They took the elevator downstairs.

Last week, local researchers, bio boosters and lots of men in dark suits from the Japanese drug company Eisai gathered in the trendy meetings room at the new Catalyst restaurant.

Floor to ceiling windows overlook a landscaped concrete plaza that joins the cluster of new and renovated mid-rises known as Technology Square. The landlord, lab developer Alexandria Properties, chose the restaurant — and the former chef of now closed Aujourd’hui — with meetings like this one in mind. Thus, 1,900-square-feet of meeting space behind the dining room can be split up into the Crick, Franklin and Watson rooms. (The rest of the restaurant is farm-to-table chic, with panelling made of old barn boards a “two-way fireplace” encased in glass.)

Before the ribbon cutting, waiters worked their way through the crowd with minted oysters on the half shell and tuna tartar. Slides with information about the H3—for “human, health and hope” — looped on two flat screens embedded in the blonde wood siding.

Betting on an approach emerging from the Broad Institute labs, the company plans on “integrating human cancer genomics with next-generation synthetic organic chemistry and tumor biology.” In other words, they plan to use genetic insights gleaned from actual cancer patients to identify therapeutic targets.

H3 Biomedicine is not your standard startup. Rather than seek out venture capital, the company arrives as a subsidiary of Japanese drug maker Eisai. In turn Eisai, which makes anti-cancer cancer drugs along with an epilepsy treatment, has invested $200 million into H3. Many gathered at the event had “Eisai” on their name tags and company president Haruo Naito flew in for the champagne toast. Click here’s for Mass High Tech’s take on the event.

Angus McQuilken, a spokesman for the Massachusetts Life Sciences Center, told the group that “If you stand in Kendall Square and throw a rock in any directions, you’ll hit a world class scientist.” Two of them are H3’s “scientific founders” Dr. Stuart Schreiber and Dr.Todd Golub, both of the Broad. The website Xconomy describes them as “scientific luminaries.”

More from that site.

 

H3 aims to discover small molecule drugs that target weak points in tumors that have been uncovered through genetic studies of people’s cancers. Fittingly, both Golub and Schreiber are founders of the Broad Institute of MIT and Harvard, one of the largest genomic research centers in the world. Schreiber, an expert at synthesizing drug compounds to home in on disease proteins, has been a founder of numerous biotech companies such as Vertex Pharmaceuticals and more recently Forma Therapeutics. Golub, a fellow scientific founder of Forma, is an authority on the genetics of cancer.

Always worth noting that much of the seed money that allows the Broad researchers to move into drug discovery comes from the feds. The National Institutes of Health database reports that for 2010 and 2011, Golub is working with grants worth $9 7 million, which included about $4 million for the Broad Cancer Center. Schreiber lists $22.3 million in grants, including $15 million money for including Broad comprehensive screening program

Is Kendall Square getting too hip? MIT adds to the boom

The Globe has a story on MIT’s plans for Kendall Square, which describes the school’s backyard as “urban desert, with unused spaces and buildings isolated by wide streets, exaggerating the sense of emptiness.”

That view is a little dated as the bleak landscape made huge progress on the cool curve this summer. In addition to a burst of new restaurants, add this to support that conclusion — it was hard to find a parking space on a recent Thursday night.

Read more of the Globe story here.

Or, take a look yourself: